<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080869</url>
  </required_header>
  <id_info>
    <org_study_id>RP-AV</org_study_id>
    <nct_id>NCT04080869</nct_id>
  </id_info>
  <brief_title>Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris</brief_title>
  <official_title>Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris: a Split-face Comparative Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acne is a chronic inflammatory dermatosis of the pilosebaceous unit. Topical treatment is the
      first choice in mild and moderate cases of acne, especially topical retinoids. Although
      topical retinoids are very effective in the treatment of acne, local cutaneous irritation
      including burning, itching, erythema, peeling or dryness, is observed in a considerable
      number of patients, resulting in low patient compliance, compromising the efficacy of the
      therapy.

      Several approaches have been proposed to address these concerns, including the use of esters
      of retinoic acid (RA) and RA precursors, such as retinol and retinaldehyde, or novel drug
      delivery systems, which present the potential for controlled release, in turn reducing the
      aforementioned occurrences.

      Encapsulation of retinoids into vesicular carriers as liposomes and ethosomes and
      nanoparticulate carriers can significantly improve their effects for the treatment of acne
      compared with commercial formulations , providing better tolerability of irritating retinoid.

      The aim of work is to assess the efficacy and tolerability of the topical application of
      Retinyl Palmitate-loaded ethosome formulation in the treatment of acne vulgaris in comparison
      to conventional formulation of classic retinoids
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Prospective, split face comparative clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The topical preparations are packed in non-identifiable jars and coded by a person who is not involved in the study the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the medication: number of inflammatory, non-inflammatory and total lesions</measure>
    <time_frame>at first and every 2 weeks during the 6-week treatment period from starting the topical application</time_frame>
    <description>counting the number of inflammatory, non-inflammatory and total lesions at first and every week during the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assessment of tolerability: interviewing the patients</measure>
    <time_frame>every 2 weeks during the 6-week treatment period from starting the topical application</time_frame>
    <description>interviewing the patients about any sign/symptom of adverse reactions (erythema, peeling, burning sensation, dryness and pruritus)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Facial Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>retinyl palmitate ethosomes arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be instructed to apply a thin film of the new formula on one side of the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tretinoin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retinyl palmitate</intervention_name>
    <description>topical retinyl palmitate loaded ethosomes</description>
    <arm_group_label>retinyl palmitate ethosomes arm</arm_group_label>
    <other_name>retinyl palmitate ethosomes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <description>topical tretinoin</description>
    <arm_group_label>tretinoin arm</arm_group_label>
    <other_name>classic retinoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with facial mild to moderate acne vulgaris

          -  Patients aged 12-40 years old

        Exclusion Criteria:

          -  Pregnant females

          -  Patients with skin condition of the face such as rosacea, perioral dermatitis, atopic
             or seborrheic dermatitis or psoriasis.

          -  Patients with known hypersensitivity to preparations containing retinoid.

          -  Patients who take any other cocomitant systemic or topical medications for acne
             vulgaris
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara M Awad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Venereology and Andrology, Assiut University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara M Awad, MD</last_name>
    <phone>+2-088-241-3911</phone>
    <email>saramawad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heba AE Aboutaleb, MD</last_name>
    <phone>+2-088-241-3911</phone>
    <email>heba.elsayed@nub.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM. Niosomes as carriers for tretinoin. II. Influence of vesicular incorporation on tretinoin photostability. Int J Pharm. 2003 Jul 24;260(2):261-72.</citation>
    <PMID>12842345</PMID>
  </reference>
  <results_reference>
    <citation>Castro GA, Ferreira LA. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv. 2008 Jun;5(6):665-79. doi: 10.1517/17425247.5.6.665 . Review.</citation>
    <PMID>18532922</PMID>
  </results_reference>
  <results_reference>
    <citation>Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol. 2006;19(1):2-16. Review.</citation>
    <PMID>16247244</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sara Mohamed Awad</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>retinoids</keyword>
  <keyword>retinyl palmitate</keyword>
  <keyword>ethosomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

